Adherium’s COPD digital intervention study

Adherium’s COPD digital intervention study

A new groundbreaking study, the 12-month MAGNIFY trial, reveals that digital medication adherence support can make a real difference for high-risk COPD patients! Here’s what the findings show:

– 23% reduction in treatment failure risk
– 11% lower exacerbation rates
– Significant benefits for patients with FEV1<80%, no previous exacerbations, or a Cambridge Multimorbidity Score > 3

With nearly 80% of 835 high-risk patients embracing this digital intervention across 164 primary care centers, it’s clear that digital solutions, like Adherium, are paving the way for better respiratory care outcomes!

Keen to learn more? Read the study abstract here: https://bit.ly/ADR-MAGNIFY